NR3C2 and congestive heart failure: The use of spironolactone, a mineralocorticoid receptor antagonist (MRA), has been associated with a significant reduction in risk of cardiac morbidity and mortality in humans [1] and dogs [2, 3] with congestive heart failure (CHF).